NCT07455240

A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of PF-07328948 Following Multiple Oral Doses in Healthy Chinese Adult Participants

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to learn about: * How PF-07328948 is changed and removed from the body after taking * Safety of PF-07328948 * The extent to which undesirable effects can be tolerated after taking PF-07328948 for the possible treatment of heart failure This study is seeking participants who: * Are healthy Chinese adults who are aged 18 years old and older * Have body mass index from 18.5 to under 28 kilograms/meter square * Have a total body weight over 50 kilograms (110 pounds) * Do not have a history of blood clots blocking an artery or vein All participants in this study will receive oral daily PF-07328948 at the study clinic for 7 consecutive days. The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe. Participants will take part in this study for around 10 weeks. During this time, participants will have 1 study visit at the study clinical and 1 contact over the phone.

Conditions

• Healthy Participant

Interventions

Type	Name	Description
DRUG	PF-07328948	Oral tablet

Timeline

• Start date: 2026-03-02
• Primary completion: 2026-04-15
• Completion: 2026-04-15
• First posted: 2026-03-06
• Last updated: 2026-03-23

Locations

1 site across 1 country: China